CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $3.50 price objective on the biotechnology company’s stock, up from their prior price objective of $2.25. Piper […]